← brief for 2026-08-19 · Slowing decline

Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real-Life Experience From a National Reference Network.

Key takeaways

Doctors gave SGLT2 inhibitors, a diabetes drug that also protects kidneys, to 59 people with a rare fat-storage disorder called lipodystrophy. They looked back at old records to track the effect on the kidneys and blood sugar. Because it only followed people already on the drug, it shows a link, not proof that the drug caused the changes. The group was small and the disease is rare, so it may not apply to most people with kidney disease.

Who did this work

Robert L · Belalem I · Vigouroux C · Dupuis H · Vantyghem MC · Simonson M · Nobecourt E · Mosbah H · Beliard S · Jellimann S · Janmaat S · Vatier C

Source

Article · PubMed, the drug frontier · 2026 Aug 19
https://pubmed.ncbi.nlm.nih.gov/42618535/